drugset / Trial / NCT05813951

Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock

NCT05813951

Unknown 140 enrolled Ain Shams University
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU

Timeline

Start
2022-12-02
Primary completion
2023-12-02
Completion
2023-12-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linezolid Other / unclassified 600 mg Intravenous
Comparator Linezolid Other / unclassified 1200 mg Intravenous

Indications

No indication recorded.